Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with or without Carboplatin and Paclitaxel in NSCLC (PS 2)
NCT02581943Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2016
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02581943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581943.